BMS’s Triple Regimen Receives European Commission Approval for Relapse/Refractory Multiple Myeloma

 BMS’s Triple Regimen Receives European Commission Approval for Relapse/Refractory Multiple Myeloma

BMS’s Triple Regimen Receives European Commission Approval for Relapse and Refractory Multiple Myeloma

Shots:

  • The approval is based on P-II ELOQUENT-3 study assessing Empliciti (elotuzumab) + pomalidomide and low-dose dexamethasone (EPd) vs pomalidomide and low-dose dexamethasone (Pd) in 117 patients with r/r MM prior treated with 2L+ therapies including lenalidomide and a proteasome inhibitor (PI) with disease progression on the last therapy
  • The P-III ELOQUENT-3 study results: The EPd doubled PFS and ORR compared to Pd alone i.e, PFS (10.25 vs 4.67mos.) indicating 46% reduction in disease progression; ORR (53.3% vs 26.3%); % of patients alive (67% vs 51%)
  • Empliciti is an immunostimulatory Ab works on a dual mechanism, activating the immune system through NK cells via the SLAMF7 pathway and targets SLAMF7 on myeloma cells, tagging NK cells mediated destruction via antibody-dependent cellular toxicity

Click here to­ read full press release/ article | Ref: BMS | Image: WSJ

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post